0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correction |

Unreported Financial Disclosures in: Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer FREE

JAMA. 2008;299(15):1775. doi:10.1001/jama.299.15.jcx80007.
Text Size: A A A
Published online

Unreported Financial Disclosures: In the Original Contribution entitled “Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer” published in the July 12, 2006, issue of JAMA (2006;296[2]:180-184) and in the Letter entitled “Computed Tomography Screening for Lung Cancer” published in the August 1, 2007, issue of JAMA (2007;298[5]:514-515), financial disclosures were not reported. See also related Correction, Letter, and Reply in this issue. The paragraph should have read as follows:

Financial Disclosures: Drs Henschke and Yankelevitz reported being listed as co-inventors for the following patent and patent applications: US Patent No. 7,274,810, “System and Method for Three-Dimensional Image Rendering and Analysis” (patent issued to CRF September 25, 2007); US Patent Application No. 10/245,782, “System, Method and Apparatus for Small Pulmonary Nodule Computer Aided Diagnosis from Computed Tomography Scans” (CRF pending patent application); US Patent Application No. 11/827,985, “System and Method for Three-Dimensional Image Rendering and Analysis” (CRF pending divisional application); US Patent Application No. 11/827,994, “System and Method for Three-Dimensional Image Rendering and Analysis” (CRF pending divisional application); US Patent Application No.10/688,267, “System, Method and Apparatus for Small Pulmonary Nodule Computer Aided Diagnosis from Computed Tomography Scans” (CRF pending patent application); US Patent Application No. 10/901,316, “System and Method for Providing Remote Analysis of Medical Data” (CRF pending patent application); US Patent Application No.10/932,443, “System and Method for Analyzing Medical Data to Determine Diagnosis and Treatment” (CRF pending patent application); US Patent Application No. 10/901,362, “System and Method for Conducting a Clinical Trial Study” (CRF pending patent application); US Patent Application No. 11/688,980, “Medical Imaging Visibility Index System and Method for Cancer Lesions” (CRF patent cooperation treaty application also pending); US Patent Application No. 11/377,031, “Method for Expanding the Domain of Imaging Software in a Diagnostic Workup” (CRF pending patent application) (foreign patent applications also pending); US Patent Application No. 11/858,855, “System and Method for Position Matching of a Patient for Medical Imaging” (CRF pending patent application); and “Medical Imaging System for Accurate Measurement Evaluation of Changes in a Target Lesion” (foreign patent applications pending) (Henschke/Yankelevitz pending patent application). Dr Henschke reported receiving compensation for serving as a member of a National Cancer Institute study section. Dr Yankelevitz reported being an inventor on a pending patent related to biopsy needles assigned to PneumRX, being a paid medical advisor to PneumRX, and holding stock in PneumRX.

Research Support: The institutions that comprise I-ELCAP have received research support over the last 10 years from National Institutes of Health grants R01-CA-63393l and R01-CA-78905; Department of Energy grant DE-FG02-96SF21260; Department of Defense grant; The City of New York, Department of Health and Mental Hygiene; New York State Office of Science, Technology and Academic Research (NYSTAR); American Cancer Society; Israel Cancer Association; The Starr Foundation; The New York Community Trust; The Rogers Family Fund; The Foundation for Lung Cancer: Early Detection, Prevention, and Treatment (with funding from the Vector Group, the parent company of Liggett Tobacco); Foundation for Early Detection of Lung Cancer; Dorothy R. Cohen Foundation, Research Foundation of Clinic Hirslanden; Yad-Hanadiv Foundation; Jacob and Malka Goldfarb Charitable Foundation; Auen/Berger Foundation; Princess Margaret Foundation; Berger Foundation; Tenet Healthcare Foundation; Ernest E. Stempel Foundation, Academic Medical Development Corporation; Empire Blue Cross and Blue Shield; Weill Medical College of Cornell University; Cornell University; New York Presbyterian Hospital; Clinic Hirslanden; Swedish Hospital; Christiana Care Helen F. Graham Cancer Center; Holy Cross Hospital; Eisenhower Hospital; Jackson Memorial Hospital Health System; and Evanston Northwestern Healthcare.

ARTICLE INFORMATION

Published Online: March 24, 2008 (doi:10.1001/jama.299.15.jcx80007).

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.